Concerning two US patents for ofatumumbab
Danish biotechnology firm Genmab reports that GlaxoSmithKline (GSK) has agreed a patent settlement with Genentech and City of Hope regarding Arzerra (ofatumumab).
GSK is Genmab’s development and commercial partner for the CD20 antibody ofatumumab, which is used in the treatment of chronic lymphocytic leukaemia.
The dispute concerned two US patents issued to Genentech and City of Hope, a not-for-profit organisation based in California, which are due to expire in December 2018.
The case was initiated by GSK in October 2009 and has been pending before the United States District Court for the Central District of California.
No further terms of the settlement have been disclosed.
Genmab says the settlement will not affect its financial guidance for 2012.